- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07708896
Evolution of Chronic Inflammatory Skin Diseases (EPICA)
monocentric retrospective-prospective observational study evaluating the clinical evolution of common chronic inflammatory skin diseases, including atopic dermatitis, psoriasis, prurigo nodularis, chronic hand eczema, and hidradenitis suppurativa. The study will collect demographic, clinical, therapeutic, and validated clinimetric data from patients aged ≥12 years. Its primary aim is to describe changes in disease severity over time. Secondary objectives include identifying demographic, clinical, and treatment-related predictors of moderate-to-severe disease and unfavorable outcomes. Data will cover a 7-year retrospective period and a 10-year prospective follow-up.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ketty Peris
- Numéro de téléphone: +390630155701
- E-mail: ketty.peris@policlinicogemelli.it
Lieux d'étude
-
-
-
Rome, Italie, 00168
- Recrutement
- Fondazione Policlinico Agostino Gemelli IRCCS
-
Contact:
- Ketty Peris, Prof
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
patients affected with inflammatory skin conditions including atopic dermatitis, prurigo nodularis, Hidradenitis suppurativa, psoriasis
La description
Inclusion Criteria:
- Age ≥12 years.
- Patients with a confirmed clinical diagnosis of atopic dermatitis (AD), prurigo nodularis (PN), psoriasis (PSO), chronic hand eczema (CHE), or hidradenitis suppurativa (HS) attending the dermatology outpatient clinics of Fondazione Policlinico Universitario A. Gemelli IRCCS.
- Availability of clinical data at baseline and at subsequent follow-up visits performed according to routine clinical practice.
Exclusion Criteria:
- Age <12 years; absence of the minimum required data (treatment start date and at least one follow-up visit with a clinical score).
- Refusal or inability to understand and sign the informed consent form.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: OTHER
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change Over Time in Eczema Area and Severity Index (EASI)
Délai: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Eczema Area and Severity Index (EASI) in participants with atopic dermatitis. EASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in SCORing Atopic Dermatitis (SCORAD)
Délai: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in SCORing Atopic Dermatitis (SCORAD) in participants with atopic dermatitis. SCORAD ranges from 0 to 103, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Patient-Oriented Eczema Measure (POEM)
Délai: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Patient-Oriented Eczema Measure (POEM) in participants with atopic dermatitis. POEM ranges from 0 to 28, with higher scores indicating greater patient-reported disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Psoriasis Area and Severity Index (PASI)
Délai: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Psoriasis Area and Severity Index (PASI) in participants with psoriasis. PASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hand Eczema Severity Index (HECSI)
Délai: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Hand Eczema Severity Index (HECSI) in participants with chronic hand eczema. HECSI ranges from 0 to 360, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Investigator's Global Assessment for Prurigo Nodularis
Délai: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change in Investigator Global Assessment (IGA) in patients with prurigo nodularis |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Itch Numerical Rating Scale (NRS)
Délai: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in itch intensity assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, where 0 indicates no itch and 10 indicates the worst imaginable itch. Higher scores indicate worse itch. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Sleep Numerical Rating Scale (NRS)
Délai: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in sleep disturbance assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, with higher scores indicating greater sleep disturbance. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Dermatology Life Quality Index (DLQI)
Délai: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Dermatology Life Quality Index (DLQI). Scores range from 0 to 30, with higher scores indicating greater impairment in dermatology-related quality of life. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hurley Stage
Délai: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in hidradenitis suppurativa severity according to Hurley staging. Hurley stage ranges from Stage I to Stage III, with higher stages indicating more severe disease. |
baseline and every 16 ± 4 weeks, up to 120 months
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Ketty Peris, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 27085
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .